Oncos Therapeutics Continues to Make Headlines as Oncolytic Virotherapy Gains Momentum

This HBH statement on cookies and related technologies applies to the use of such technologies when you visit this website.

What are cookies and why we use them?

Cookies are small text files stored on your device by websites you visit.

Cookies alone cannot be used to identify you, but they may be linked directly or indirectly to you when combined with other information. In these cases, cookies may be treated as personal data. We make no effort to identify you personally from cookies.

Cookies can either be session cookies (they last only until you close your browser) or persistent (they remain on your computer or device until you delete them). Session cookies are usually used to remember relevant settings of your browsing session. Persistent cookies may typically be used for targeted advertising and gaining insight on how you use our website. We use both session and persistent cookies. Our persistent cookies are set to expire no later than two years after last refresh.

We may use cookies to collect information on the use of our web services and on our audience, and to enable some features on the website or remember the choices our users make.

We use cookies to:

• Enable site functionality. Website uses cookies that support site functionality, e.g. to help you access secure areas. Where permitted by applicable law, HBH may set these types of cookies without requesting your consent.
• Collect statistical information on the use of our website. This helps us measure the effect of our marketing efforts and guides us in providing you with a better service. Depending on your browser settings, some of this information may also be shared with third-party service providers (e.g. Google Analytics).
• Provide relevant content. Cookies allow us to tailor site's content to better match your needs and interests.

Please note that if you disable cookies, some website functionality may be limited.